http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

StockMarketWire.com
Allied Minds, an innovative US science and technology development and commercialisation company, will announce its full year 2014 results at 7 a.m. on 28 April.

Allied Minds will also host a capital markets day event on the same day, to be held at Etc. Venues St Paul's, 200 Aldersgate Street, EC1A 4HD.

Allied Minds' Subsidiary SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman
· SciFluor's recent advancements in its pipeline, comprised of two lead compounds and additional discovery assets using the strategic incorporation of fluorine to create best-in-class drugs, generated investor interest.
· SciFluor's plans to develop fluorine-containing new chemical entities (NCEs) across multiple disease states will benefit from the addition of William Koster, whose accomplishments include success in senior executive roles in small molecule drug discovery and early clinical development at Neurogen Corp. and Bristol-Myers Squibb Co.

Appointment of New Non-Executive Chairman
Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, today announces that Mr. Peter Dolan will be appointed to the role of Non-Executive Chairman of the board of directors of the Company ("Board"), with effect from the conclusion of the Company's Annual General Meeting on 28 May 2015. Mr. Dolan will replace the current Executive Chairman, Mr. Mark Pritchard, who will remain on the Board in an executive capacity in the short term but intends to step down from the Board later in the year, although he is expected to continue to be actively engaged with the Company. Mr. Pritchard founded Allied Minds in 2004 and has been directly involved in its strategic direction and growth since inception, most recently taking the role of Chairman of the Board as the Company listed on the Main Market of the London Stock Exchange in June 2014. The appointment of Mr. Dolan, an independent non-executive director, will further the Company's compliance with best practices of the UK Corporate Governance Code.

Placing of Shares in Allied Minds plc
20 May 2015

Further to the announcement released on 19 May 2015, Invesco Asset Management Limited, in its capacity as agent for and on behalf of its discretionary managed clients ("Invesco") has sold 16 million ordinary shares of Allied Minds (the "Placing Shares") at a price of 565 pence per share, raising gross sale proceeds of £90.4 million.

The sale on behalf of Invesco was completed via an accelerated bookbuild to institutional investors conducted by Jefferies International Limited ("Jefferies") and Numis Securities Limited ("Numis") as joint bookrunners (the "Placing"). Allied Minds will not receive any proceeds from the Placing.

Following settlement of the Placing, Invesco's discretionary managed clients are expected to hold approximately 34.5 per cent. of the Company's issued share capital.

The proceeds of the Placing are payable in cash on usual settlement terms, and closing of the Placing is expected to occur on a T+2 basis on 22 May 2015, subject to the satisfaction or waiver of certain customary conditions.

Invesco has indicated that, following completion of the Placing, it intends to remain a significant, long term shareholder of the Company.

Annual General Meeting
Allied Minds plc, an innovative U.S.-focused science and technology development and commercialisation company, is holding its Annual General Meeting (AGM) today. No new information on current trading will be given during the meeting.

The Company will release its 2015 Half Yearly Report on 27th August 2015.

StockMarketWire.com
Allied-Bristol Life Sciences - a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Company - has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Whitman's lab at the Harvard School of Dental Medicine.

Malcolm Whitman, PhD, Professor of Developmental Biology, and Tracy Keller, PhD, an instructor in the Department of Developmental Biology, have identified the mechanism of action behind a known natural product, halofuginone (HF).

HF is a chemical compound based on an active ingredient in the root of the blue evergreen hydrangea (Dichroa febrifuga), which has been used in traditional Chinese medicine for centuries.

Building on previous studies conducted with Mark Sundrud, PhD, and Anjana Rao, PhD, at Boston Children's Hospital, Professor Whitman's lab, in collaboration with Professor Ralph Mazitschek, PhD, at the Center for Systems Biology at Massachusetts General Hospital, has shown that HF works through inhibition of Prolyl-tRNA synthetase, which leads to activation of an amino acid restriction (AAR) response pathway.

Based on this novel and differentiated mechanism, several lead molecules have been identified by the groups at HMS and MGH that have the potential to lead to effective therapy for several conditions including fibrotic and autoimmune diseases.

StockMarketWire.com
Allied Minds posts a loss of $39.1m for the six months to the end of June compared with $27.2m a year ago.

Revenue fell to $1.5m (HY14: $2.9m) which was primarily attributable to the lower product revenue at RF Biocidics, offset by the grant revenue at SiEnergy from the ARPA-E award.

Revenues at CryoXtract and SoundCure remained relatively consistent when compared to the same period in the prior year.

Cost of revenue was lower by $1.2 million, at $0.7 million for the six months ended 30 June 2015 (HY14: $1.9m) as a result of the lower sales in the period, when compared to the same period in the prior year.

The company also announced that its joint venture with Bristol-Myers Squibb Co, Allied-Bristol Life Sciences, has licensed a proprietary platform technology from Yale University, developed in the laboratory of Dr. David Spiegel.

The proprietary platform, and associated lead molecules known as Antibody-Recruiting molecules (ARMs), provide a novel approach for the treatment of cancer.

Allied Minds Announces the Formation of HawkEye 360
● The company will use small satellites in low Earth orbit (LEO) to collect data, perform analytics and generate reports on wireless signals worldwide that can be used to monitor and track ships, planes and other transportation networks across air, land and sea, and assist with emergency response.

● The three founders of HawkEye 360 bring valuable experience: Mr. Chris DeMay previously worked for the U.S. National Reconnaissance Office, leading programs for satellite development. Dr. Charles Clancy and Dr. Bob McGwier of Virginia Tech's Hume Center for National Security and Technology developed the associated technology for the complex RF signal processing.

http://www.moneyam.com/action/news/showArticle?id=5114795

This is a very detailed report from a hedge fund on why NOT to invest in ALM:

http://kerrisdalecap.com/wp-content/uploads/2015/09/Allied-Minds-Report.pdf

StockMarketWire.com
Allied Minds subsidiary Precision Biopsy has raised $33.6m in new equity investments as the company embarks on a global commercialisation strategy for its ClariCore Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures. Precision Biopsy also plans to accelerate the development of its Focal Therapy program, which seeks to provide targeted, localised therapy to the prostate gland by using the same optical tissue-targeting technology found in the ClariCore system.

Woodford Investment Management led this round of financing, which included Allied Minds, and demonstrates the continued support for the business and these growth initiatives.

StockMarketWire.com
Allied Minds subsidiary, Spin Transfer Technologies, has successfully demonstrated its Spin Transfer Magneto-Resistive Random Access Memory technology through the production of a working prototype device.

This milestone achievement also proved the company's advanced prototyping magnetics processing line at its facility in Fremont, California, is now fully operational.

The prototypes incorporate proprietary, performance-enhancing 'spin-filtering' technology, and were fabricated on industry standard CMOS wafers sourced from a high volume Asian foundry supplier. STT was able to demonstrate ST-MRAM that delivers fully operational integrated memory functionality.

StockMarketWire.com
Allied Minds saw positive progress in 2015 with its subsidiaries meeting or exceeding commercial milestones in nearly all instances.

Chief executive Chris Silva said: "We have embarked on exciting collaborations with industry leaders such as Bristol-Myers Squibb, Intel, AMD and Google; raised material third-party funding to accelerate the development of two of our key subsidiaries; and seen the number of commercialisation phase subsidiaries double to six.

"Our US academic and federal partner network is continuing to flourish and has been highly productive over the year. We reviewed more than 5,000 new technologies and engaged with over 90 new research institutions, reflecting the growing recognition of the strengths of Allied Minds as a commercialisation partner. We continue to apply our rigorous selection and due diligence processes to these new technologies and are confident in the potential of our pipeline.

"The range and depth of our achievements during 2015 has laid strong foundations for Allied Minds to continue to generate further value in 2016 and beyond."

all good news, but losses, are potent, rev down, cash to last don't know, no
directors buying receintly none. BB. s/p 440p ps. holder reduces.

StockMarketWire.com
Allied-Bristol Life Sciences - a biopharmaceutical enterprise jointly owned by Allied Minds and Bristol-Myers Squibb Co - has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway.

The Wnt pathway plays a key role in the development and progression of a number of cancers affecting large numbers of patients.

iβeCa Therapeutics will focus on further discovery and development activities needed to identify candidates for human clinical testing.

StockMarketWire.com
Allied Minds, through its newly formed subsidiary, ABLS Capital, it has secured investment commitments of $80 million to fund up to 10 potential lead optimisation programmes of promising drug development opportunities that have successfully completed an initial candidate feasibility programme.

Under the terms of the ABLS partnership formed between Allied Minds and BMS in 2014, BMS is committed to fund an additional $20 million along with these commitments.

Investors in ABLS Capital include Woodford Investment Management (committing to fund up to $40 million), Invesco Asset Management (committing to fund up to $20 million), as well as Allied Minds and others.

ABLS is a drug discovery company focused on identifying and developing biopharmaceutical innovations from leading U.S. universities and research institutions that it believes have significant therapeutic and commercial potential. ABLS focuses on early-stage opportunities in key therapeutic areas, including fibrosis, cardiovascular, oncology, immunology and genetically defined diseases. ABLS forms and funds new subsidiary companies to conduct an initial feasibility programme on identified discoveries. Upon completion of a successful feasibility program, ABLS arranges for additional funds to be provided to such ABLS subsidiary for the next stage of development. ABLS Capital will provide 80% of the funds for this critical next stage, and together with the 20% of funds provided by BMS, will ensure that up to ten ABLS subsidiaries will have the necessary capital to seek to identify pre-clinical drug candidates. Chris Silva, CEO of Allied Minds, said: "This is another exciting step forward for achieving the goals of ABLS, which was formed less than two years ago. Backed by supportive new investors and together with our partner Bristol-Myers Squibb, we have secured sufficient funding commitments for the pre-clinical development of up to ten drug candidates. Each of these have the potential to address areas of great unmet medical need across very sizeable markets."

FOR RELEASE ON 13 MAY 2016

Allied Minds plc (the "Company" or the "Group")

Director / PDMR Shareholding

Allied Minds plc (LSE: ALM), an innovative U.S.-focused science and technology development and commercialisation company, announces that it received notification from Marc Eichenberger, Chief Operating Officer, a person discharging managerial responsibility ("PDMR"), regarding the sale of the Company's ordinary shares of one pence each ("Ordinary Shares").

The Company was notified that, on 09 May 2016, Mr. Eichenberger sold 37,980 Ordinary Shares at a price of 344.6083 pence per share, and on 10 May 2016, Mr. Eichenberger sold 11,262 Ordinary Shares at a price of 335.4364 pence per share.

Interesting stock will do some research.

Be careful mitzy. This is really a venture capital company, which is attempting to invest in high risk, but hopefully very profitable research. I have owned the stock from the outset, but took profit when the sp was up in the 700p level. I agree it is dabbling in very interesting areas, but with the associated risks attached!

Thanks Harry I realise its a high risk stock and it has fallen again today will watch it for the time being.

StockMarketWire.com
Allied Minds has secured a $20 million, one-year revolving debt facility from Silicon Valley Bank.

The facility is secured over certain assets of the group. To secure the facility, the group was required to meet certain financial strength tests set by SVB.

Chief executive Chris Silva said: "We are pleased to have SVB's support as we continue to build and develop our portfolio and look forward to what we anticipate will be a long-term relationship with SVB. The SVB facility further diversifies our capital structure and is a powerful endorsement of the Group's growth and development prospects."

Separately, the group also said its subsidiary, ABLS II, had raised $15 million.

On 25 May, Allied-Bristol Life Sciences, LLC announced that it had successfully completed the drug candidate feasibility programme at ABLS II, LLC (ABLS II) for novel small molecule therapeutics for the treatment of fibrotic and autoimmune diseases

ABLS II has now raised $15 million of new equity in a Series A Preferred round from investors including ABLS Capital, LLC ($12 million) and Bristol-Myers Squibb Company ($3 million) to fund further development of the lead optimisation programme

To fund its portion of the ABLS II financing, ABLS Capital has raised $12 million of new equity in a Class B shares round from investors including Woodford Investment Management ($6 million), Invesco Asset Management ($3 million) and Allied Minds

Allied Minds' economic interest in ABLS II is 35.95%, arising from its 80% interest in ABLS and 30.25% interest in ABLS Capital

Should this next lead optimisation phase prove successful, Bristol-Myers Squibb has the right to acquire Allied Minds' interest in ABLS II at a pre-determined multiple of invested capital.